Main Reference
Infectious Disease

Subscribe to COVID-19

AV001-004, AV-001 for Pneumonia

Internal Medicine Infectious Disease Pulmonology Heart and Vascular COVID-19 Influenza Respiratory Distress Syndrome Bacterial Infectious Diseases Lung Disease Infectious Disease Vascular Disease Adult Subjects

A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy. The purpose of this study is to examine the safety, tolerability and efficacy of AV-001 Injection administration daily to the earlier of day 28 or EOT (day prior to hospital discharge). A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be recruited from up to 25 participating institutions/hospitals. Patients will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).

DAS181-3-01, DAS181, for Parainfluenza

Cancer Internal Medicine Infectious Disease Pulmonology COVID-19 Airway Disease Infectious Disease Pediatric Subjects Adult Subjects

This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.

It also contains a sub-study to enroll patients with severe COVID-19.

Transcranial direct current stimulation (tDCS) for the treatment of fatigue in post-COVID-19 patients

Radiology Infectious Disease Endocrinology COVID-19 Diabetes Infectious Disease Adult Subjects Female Subjects Male Subjects

The objective of this study is to investigate the short- and long-term effects of multiple sessions of 4 mA M1 tDCS on fatigue and brain activity in recovered COVID-19 patients using established measures of perception of fatigue, performance fatigability, and cerebral glucose uptake. Our central hypothesis is that tDCS will improve fatigue short- and long-term, and thus will improve quality of life (QOL) in recovered COVID-19 patients and that these changes will be associated with alterations in brain activity.

Post COVID-19

Internal Medicine Infectious Disease COVID-19 Adult Subjects Female Subjects Male Subjects

ECP Registry

Internal Medicine Pulmonology Infectious Disease Lung Disease COVID-19 Adult Subjects Female Subjects Male Subjects

The primary aims of this study is to determine the efficacy and tolerability of Extracorporeal Photopheresis (ECP) for the treatment of either Refractory Bronchiolitis Obliterans Syndrome (BOS) patients (258 at cessation of enrollment April 7, 2022) or Newly Diagnosed (22 as of enrollment Hold February 2022) Bronchiolitis Obliterans Syndrome patients after lung transplantation. In compliance with the Centers for Medicare and Medicaid Services' (CMS) Coverage with Evidence Development (CED) decision, the study will collect specified demographic, comorbidity, treatment, and outcome data exclusively for Medicare beneficiaries who are treated with ECP for either refractory or New BOS.